Neuland Laboratories Ltd
NSE:NEULANDLAB
Neuland Laboratories Ltd
Depreciation & Amortization
Neuland Laboratories Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
Depreciation & Amortization
₹639.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Depreciation & Amortization
₹17B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Depreciation & Amortization
₹10.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Depreciation & Amortization
₹25.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Depreciation & Amortization
₹8.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Depreciation & Amortization
₹4B
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuland Laboratories Ltd
Glance View
Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.
See Also
What is Neuland Laboratories Ltd's Depreciation & Amortization?
Depreciation & Amortization
639.6m
INR
Based on the financial report for Dec 31, 2024, Neuland Laboratories Ltd's Depreciation & Amortization amounts to 639.6m INR.
What is Neuland Laboratories Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
12%
Over the last year, the Depreciation & Amortization growth was 17%. The average annual Depreciation & Amortization growth rates for Neuland Laboratories Ltd have been 12% over the past three years .
You don't have any saved screeners yet